Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapering Systemic Immunosuppressive Therapy in Psoriatic Arthritis (ATTRACTOR)
NCT04610476Phase 3Unknown
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Oct 2020
- Primary completion
- Oct 2024
- Modality
- Antibody Fragments, Polymer-based Nanoparticles, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of prednisolone, 5-aminosalicylic acid + sulphasalazine, leflunomide, methotrexate, tofacitinib oral solution in psoriatic arthritis (PsA), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Status: unknown.
02
Drugs
prednisolone5-aminosalicylic acid + sulphasalazineleflunomidemethotrexatetofacitinib oral solution
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04610476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610476.